Novel humanized anti‐CD20 antibody BM‐ca binds to a unique epitope and exerts stronger cellular activity than others

Abstract Cellular activity of BM‐ca, a novel humanized anti‐CD20 antibody, was quantitatively compared with that of two other anti‐CD20 antibodies used for clinical practice, rituximab and ofatumumab. The results of a complement‐dependent cytotoxicity (CDC) assay revealed that the strongest antibody...

Full description

Bibliographic Details

Published in:	Cancer Medicine
Main Authors:	Hideaki Kobayashi, Yuka Matsunaga, Yumiko Uchiyama, Kenji Nagura, Yasuhiko Komatsu
Format:	Article
Language:	English
Published:	Wiley 2013-04-01
Subjects:	Anti‐CD20 antibody cancer chemotherapeutics epitope lymphoma ofatumumab rituximab
Online Access:	https://doi.org/10.1002/cam4.60